NCT05907330View on ClinicalTrials.gov

Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

March 31, 2026

Conditions

Ulcerative Colitis

Interventions

DRUG

CU104

CU104 will administer the study drug once a day after a meal

DRUG

Placebo

Placebo will administer the study drug once a day after a meal

All Listed Sponsors

lead

Curacle Co., Ltd.

INDUSTRY